Figure 2.
Efficacy evaluation by disease activity category in patients who switched from intravenous to subcutaneous tocilizumab (TCZ IV/SC) and who continued TCZ‐SC. A, Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28‐ESR), and B, Clinical Disease Activity Index (CDAI) score.